REG - Trellus Health PLC - Grant of Share Options

Trellus HealthAnnouncement

19/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260119:nRSS3331Pa&default-theme=true

RNS Number : 3331P  Trellus Health PLC  19 January 2026

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Grant of Share Options

 

LONDON, U.K. AND NEW YORK, U.S. (19 January 2026). Trellus Health® plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programs and value-based solutions to manage complex chronic
conditions, announces that the Board has granted options over a total of
807,541 ordinary shares of £0.0006 in the capital of the Company (the "Share
Options") to Kevin Murphy, Chairman of the Company (the "Option Holder").

 

The Share Options, which have been issued in line with the Company's existing
share option plan (the "Option Plan"), have an exercise price of 0.525p per
ordinary share. This is in line with the exercise price of the Loan Note,
entered into with Mount Sinai on November 24, 2025. The Share Options are
subject to lock-in provisions, being 12 months from the date the Share Options
are exercised.

 

The Share Options vest and become exercisable in twelve (12) equal quarterly
instalments (rounded up to the nearest whole share) thereafter of which the
first instalment shall vest three months after the grant date and the twelfth
shall vest 39 months after the vesting commencement date.

 

The Share Options are subject to the rules of the Option Plan and the relevant
award documentation, including customary good leaver and bad leaver
provisions.

 

The independent directors consider that the award is fair and reasonable
insofar as the Company's shareholders are concerned and believe it
appropriately aligns the Chairman's interests with those of shareholders.

 

Capitalised terms used but not otherwise defined in this announcement shall
have the meanings given to them in the Company's announcement released on 30
December 2025.

 

For further information please contact:

 

 Trellus Health plc                                                  https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder          Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)               Tel: +44 (0)20 7496 3000
 Philip Davies / James Todd / Patrick Weaver

 Walbrook PR                         Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                     (mailto:trellus@walbrookpr.com)
 Paul McManus / Lianne Applegarth /  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/

 Alice Woodings                      +44 (0)7407 804 654

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer
hospitalisations and a reduction of over 70% in emergency room visits. Given
the common emotional and mental health struggles associated with a variety of
chronic conditions, Trellus Health considers its approach to have potential
utility and demand across many conditions.

 

Trellus Health also offers a seamless solution for pharmaceutical partners
from clinical trials to commercialisation, harnessing resilience-based methods
to drive both trial and patient support success by empowering patients to stay
engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both world-leading experts at treating and healing
both the physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Kevin Laurence Murphy

 2    Reason for the notification

 a)   Position/status                                              Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Trellus Health plc

 b)   LEI                                                          2138002FHWJSR8YKP295

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Options over ordinary shares of £0.0006 each in the Company

      Identification code                                          GB00BNNFM402

 b)   Nature of the transaction                                    Grant of options over shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)                  Volume(s)
                                                                                     £0.00525 exercise price   807,541

 d)   Aggregated information

      - Aggregated volume                                          N/A

      - Price                                                      N/A

 e)   Date of the transaction                                      16 January 2026

 f)   Place of the transaction                                     Outside of trading venue - off market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBPMBTMTBBTJF



            Copyright 2019 Regulatory News Service, all rights reserved